OKYO Pharma Limited(OKYO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

OKYO OKYO Pharma Limited

Not Yet Opened 04-13 16:00:00 EDT

1.53

+0.02

+1.32%

High1.68	Low1.47	Vol119.95K
Open1.49	D1 Closing1.51	Amplitude13.91%
Mkt Cap80.29M	Tradable Cap47.97M	Total Shares52.48M
T/O183.26K	T/O Rate0.38%	Tradable Shares31.35M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"OKYO","market":"US","secType":"STK","nameCN":"OKYO Pharma Limited","latestPrice":1.53,"timestamp":1776110400000,"preClose":1.51,"halted":0,"volume":119951,"delay":0,"changeRate":0.013245033112582794,"floatShares":31353600,"shares":52479300,"eps":-0.1114,"marketStatus":"Not Yet Opened","change":0.02,"latestTime":"04-13 16:00:00 EDT","open":1.49,"high":1.68,"low":1.47,"amount":183259.5904321,"amplitude":0.139073,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.1114,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1776153600000},"marketStatusCode":0,"adr":0,"adrRate":65,"listingDate":1652760000000,"exchange":"NASDAQ","adjPreClose":1.51,"postHourTrading":{"tag":"盘后","latestPrice":1.62,"preClose":1.53,"latestTime":"19:38 EDT","volume":419,"amount":650.6563,"timestamp":1776123528925,"change":0.09,"changeRate":0.058824,"amplitude":0.058824},"volumeRatio":1.17526},"requestUrl":"/m/hq/s/OKYO/tweets","defaultTab":"tweets","newsList":[{"id":"2625937439","title":"OKYO Pharma to Showcase Urcosimod Data and Convene Key Advisory Board at 2026 ASCRS Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2625937439","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625937439?lang=en_us&edition=fundamental","pubTime":"2026-04-07 19:33","pubTimestamp":1775561605,"startTime":"0","endTime":"0","summary":"An announcement from OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) is now available. On April 7, 2026, OKYO Pharma announced it will convene a key ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/okyo-pharma-to-showcase-urcosimod-data-and-convene-key-advisory-board-at-2026-ascrs-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/okyo-pharma-to-showcase-urcosimod-data-and-convene-key-advisory-board-at-2026-ascrs-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OKYO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625893258","title":"OKYO Pharma plans new urcosimod trial for neuropathic corneal pain in H1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2625893258","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625893258?lang=en_us&edition=fundamental","pubTime":"2026-04-07 19:01","pubTimestamp":1775559669,"startTime":"0","endTime":"0","summary":"OKYO Pharma scheduled a Scientific Advisory Board meeting during 2026 ASCRS Annual Meeting to review clinical data for lead candidate urcosimod and shape next-stage development plans.Phase 2 proof-of-concept results in neuropathic corneal pain were described as showing encouraging efficacy signals with a favorable safety profile.OKYO plans to initiate next urcosimod clinical trial in first half of 2026, supported by FDA Fast Track status for neuropathic corneal pain.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OKYO Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 07, 2","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDL3DBmFg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKYO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620221666","title":"OKYO Pharma Director Boosts Stake as Lead Eye-Pain Drug Advances Toward Phase 2b/3","url":"https://stock-news.laohu8.com/highlight/detail?id=2620221666","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620221666?lang=en_us&edition=fundamental","pubTime":"2026-03-19 22:28","pubTimestamp":1773930503,"startTime":"0","endTime":"0","summary":"OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) just unveiled an announcement. On March 19, 2026, OKYO Pharma announced that non-executive director J...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/okyo-pharma-director-boosts-stake-as-lead-eye-pain-drug-advances-toward-phase-2b-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/okyo-pharma-director-boosts-stake-as-lead-eye-pain-drug-advances-toward-phase-2b-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","OKYO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620267202","title":"OKYO Pharma director John Brancaccio buys 5,000 shares at USD 1.61","url":"https://stock-news.laohu8.com/highlight/detail?id=2620267202","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620267202?lang=en_us&edition=fundamental","pubTime":"2026-03-19 22:01","pubTimestamp":1773928862,"startTime":"0","endTime":"0","summary":"Non-Executive Director John Brancaccio bought 5,000 OKYO ordinary shares on Nasdaq at USD 1.61.The purchase increased his total holding to 31,201 shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OKYO Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 19, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDLDxnYt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"OKYO Pharma director John Brancaccio buys 5,000 shares at USD 1.61","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OKYO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620024219","title":"Okyo Pharma CDO, director acquire shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2620024219","media":"TIPRANKS","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620024219?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:37","pubTimestamp":1773920229,"startTime":"0","endTime":"0","summary":"OKYO Pharma (OKYO) announced it has been informed that Gary Jacob, Chief Development Officer and Director, has acquired 30,980 of the Company’s ord...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/okyo-pharma-cdo-director-acquire-shares-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/okyo-pharma-cdo-director-acquire-shares-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","OKYO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620632228","title":"OKYO Pharma Announces Chief Development Officer and Director Acquires Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2620632228","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620632228?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:00","pubTimestamp":1773918000,"startTime":"0","endTime":"0","summary":"LONDON and NEW YORK, March  19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neurop","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/19/3258842/0/en/OKYO-Pharma-Announces-Chief-Development-Officer-and-Director-Acquires-Shares.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OKYO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620291668","title":"OKYO Pharma Chief Development Officer Gary S. Jacob files Form 3 initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620291668","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620291668?lang=en_us&edition=fundamental","pubTime":"2026-03-19 08:38","pubTimestamp":1773880710,"startTime":"0","endTime":"0","summary":"OKYO Pharma reported an initial statement of beneficial ownership for Gary Jacob, a director and Chief Development Officer. The filing shows he beneficially owned 108,920 shares of common stock. It also lists stock options exercisable for 21,154 shares at a USD 2.13 exercise price. Additional options are shown exercisable for 102,653 shares at a USD 1.6 exercise price.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OKYO Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL10lFXn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OKYO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620291503","title":"OKYO Pharma Director and 10% Owner Gabriele M Cerrone Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620291503","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620291503?lang=en_us&edition=fundamental","pubTime":"2026-03-19 08:36","pubTimestamp":1773880588,"startTime":"0","endTime":"0","summary":"OKYO Pharma reported an initial statement of beneficial ownership by director and 10% owner Gabriele Cerrone. Cerrone reported direct beneficial ownership of 10.53 million shares of common stock. The date of the event requiring the statement was March 18, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OKYO Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL9s0Bvg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKYO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620588452","title":"Okyo Pharma reports results from Phase 2a trial of urcosimod","url":"https://stock-news.laohu8.com/highlight/detail?id=2620588452","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620588452?lang=en_us&edition=fundamental","pubTime":"2026-03-18 19:22","pubTimestamp":1773832972,"startTime":"0","endTime":"0","summary":"OKYO Pharma (OKYO) announced new positive findings from an exploratory analysis of patient-reported outcomes in its recently completed Phase 2a tri...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/okyo-pharma-reports-results-from-phase-2a-trial-of-urcosimod-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/okyo-pharma-reports-results-from-phase-2a-trial-of-urcosimod-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OKYO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620237942","title":"OKYO Pharma reports Phase 2a data showing improved quality-of-life scores with 0.05% urcosimod in neuropathic corneal pain patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2620237942","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620237942?lang=en_us&edition=fundamental","pubTime":"2026-03-18 19:02","pubTimestamp":1773831745,"startTime":"0","endTime":"0","summary":"OKYO Pharma reports Phase 2a data showing improved quality-of-life scores with 0.05% urcosimod in neuropathic corneal pain patients. OKYO Pharma reported new findings from an exploratory analysis of patient-reported outcomes in its completed Phase 2a randomized, double-masked, placebo-controlled trial of urcosimod 0.05% for neuropathic corneal pain. The quality-of-life data will be presented in the future at the ARVO 2026 Annual Meeting. In the intent-to-treat population, patients received urcosimod (n=6) or placebo (n=6) for 12 weeks. Reported mean change from baseline included “enjoying life/relationships” of 4.5 with urcosimod versus 0 with placebo on a 0–10 scale. The company also said the Phase 2a results included pain reductions measured by the visual analogue scale and exploratory signals related to corneal nerve structure.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL64RY37:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","BK4112","SG9999014013.SGD","SG9999014039.USD","NDAQ","BK4585","OKYO","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","LU2095319765.USD","BK4588","LU2210149790.SGD","IE00BKPKM429.USD","SG9999014021.USD","BK4139","LU0314104364.USD","IE00B3QW5Z07.USD","LU2210150020.SGD","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613773543","title":"OKYO Pharma’s Urcosimod NCP Data Selected for Presentation at ARVO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2613773543","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613773543?lang=en_us&edition=fundamental","pubTime":"2026-02-24 00:29","pubTimestamp":1771864148,"startTime":"0","endTime":"0","summary":"OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) has shared an update. On February 23, 2026, OKYO Pharma announced that an abstract detailing the firs...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/okyo-pharmas-urcosimod-ncp-data-selected-for-presentation-at-arvo-2026?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/okyo-pharmas-urcosimod-ncp-data-selected-for-presentation-at-arvo-2026?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OKYO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613733290","title":"OKYO Pharma Abstract Earns Presentation Slot at ARVO 2026 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2613733290","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613733290?lang=en_us&edition=fundamental","pubTime":"2026-02-24 00:00","pubTimestamp":1771862413,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OKYO Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire  on February 23, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDL4TphnS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","NDAQ","SG9999014021.USD","BK4588","SG9999014005.SGD","LU2210149790.SGD","BK4585","OKYO","LU0314104364.USD","IE00B3QW5Z07.USD","BK4112","LU2210150020.SGD","IE00BKPKM429.USD","IE00B64PRP62.GBP","SG9999014039.USD","BK4139","IE00BGHQF748.EUR","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613735951","title":"OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2613735951","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613735951?lang=en_us&edition=fundamental","pubTime":"2026-02-24 00:00","pubTimestamp":1771862400,"startTime":"0","endTime":"0","summary":"LONDON and NEW YORK, Feb.  23, 2026  (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neurop","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/23/3242801/0/en/OKYO-Abstract-Selected-for-Presentation-at-Premier-Global-Ophthalmology-Congress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OKYO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612612962","title":"Piper Sandler Initiates Coverage on OKYO Pharma With Overweight Rating, $7 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2612612962","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612612962?lang=en_us&edition=fundamental","pubTime":"2026-02-20 20:15","pubTimestamp":1771589733,"startTime":"0","endTime":"0","summary":"OKYO Pharma (OKYO) has an average rating of Buy and mean price target of $8, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and r","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OKYO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612529265","title":"OKYO Pharma Initiated at Overweight by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2612529265","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612529265?lang=en_us&edition=fundamental","pubTime":"2026-02-20 18:19","pubTimestamp":1771582740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OKYO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 20, 2026 05:19 ET (10:19 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKYO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612265913","title":"Okyo Pharma initiated with an Overweight at Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2612265913","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612265913?lang=en_us&edition=fundamental","pubTime":"2026-02-20 18:12","pubTimestamp":1771582348,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Biren Amin initiated coverage of Okyo Pharma (OKYO) with an Overweight rating and $7 price target The firm is positive on the...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/okyo-pharma-initiated-with-an-overweight-at-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/okyo-pharma-initiated-with-an-overweight-at-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","OKYO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611970384","title":"OKYO Pharma Announces Public Offering of Ordinary Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2611970384","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611970384?lang=en_us&edition=fundamental","pubTime":"2026-02-13 05:01","pubTimestamp":1770930060,"startTime":"0","endTime":"0","summary":"LONDON and NEW YORK, Feb.  12, 2026  (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq:OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropa","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/12/3237645/0/en/OKYO-Pharma-Announces-Public-Offering-of-Ordinary-Shares.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKYO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610175959","title":"OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2610175959","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610175959?lang=en_us&edition=fundamental","pubTime":"2026-02-11 23:09","pubTimestamp":1770822540,"startTime":"0","endTime":"0","summary":"LONDON and NEW YORK, Feb.  11, 2026  (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq:OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/11/3236441/0/en/OKYO-Pharma-Announces-Transition-of-At-The-Market-Equity-Offering-Facility-to-Leerink-Partners.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4215","EQR","BK4585","BK4588","OKYO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610313009","title":"OKYO Pharma Launches $50 Million At-the-Market Share Offering With Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2610313009","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610313009?lang=en_us&edition=fundamental","pubTime":"2026-02-11 19:39","pubTimestamp":1770809955,"startTime":"0","endTime":"0","summary":"OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) has shared an announcement. On February 10, 2026, OKYO Pharma Ltd entered into a Sales Agreement with...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/okyo-pharma-launches-50-million-at-the-market-share-offering-with-leerink-partners?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/okyo-pharma-launches-50-million-at-the-market-share-offering-with-leerink-partners?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","OKYO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610628324","title":"OKYO Pharma ernennt Flavio Mantelli zum Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2610628324","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610628324?lang=en_us&edition=fundamental","pubTime":"2026-02-10 21:00","pubTimestamp":1770728428,"startTime":"0","endTime":"0","summary":"OKYO Pharma Ltd. hat die Ernennung von Dr. Flavio Mantelli, MD, PhD, zum Chief Medical Officer bekanntgegeben. Zuvor wurde bereits Robert Dempsey als neuer CEO des Unternehmens vorgestellt. Dr. Mantelli war mageblich an der Entwicklung und Zulassung von Oxervate beteiligt und wird künftig die klinische Entwicklung und Strategie des Unternehmens insbesondere im Bereich neuropathischer Hornhautschmerz leiten.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OKYO Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire  on February 10, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nNDLbzZx1b:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BKPKM429.USD","SG9999014013.SGD","IE00B64PRP62.GBP","SG9999014005.SGD","SG9999014021.USD","SG9999014039.USD","BK4588","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","BK4112","LU2210149790.SGD","LU2095319765.USD","LU2210150020.SGD","OKYO","LU0314104364.USD","BK4585","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.okyopharma.com","stockEarnings":[{"period":"1week","weight":-0.0255},{"period":"1month","weight":-0.0783},{"period":"3month","weight":-0.508},{"period":"6month","weight":-0.2609},{"period":"1year","weight":0.4299},{"period":"ytd","weight":-0.2609}],"compareEarnings":[{"period":"1week","weight":0.0412},{"period":"1month","weight":0.036},{"period":"3month","weight":-0.0111},{"period":"6month","weight":0.0315},{"period":"1year","weight":0.285},{"period":"ytd","weight":0.0061}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease; in phase 1 clinical trial for the treatment of neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201, which is in preclinical trial for the treatment of dry eye disease and neuropathic chronic pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":0.016922},{"month":2,"riseRate":0.25,"avgChangeRate":-0.048425},{"month":3,"riseRate":0.5,"avgChangeRate":-0.0442},{"month":4,"riseRate":0.5,"avgChangeRate":-0.011236},{"month":5,"riseRate":0.666667,"avgChangeRate":0.132873},{"month":6,"riseRate":0.5,"avgChangeRate":-0.013367},{"month":7,"riseRate":1,"avgChangeRate":0.208942},{"month":8,"riseRate":0.5,"avgChangeRate":0.008913},{"month":9,"riseRate":0.25,"avgChangeRate":-0.093671},{"month":10,"riseRate":0.5,"avgChangeRate":0.07182},{"month":11,"riseRate":0,"avgChangeRate":-0.142327},{"month":12,"riseRate":0.75,"avgChangeRate":0.059341}],"exchange":"NASDAQ","name":"OKYO Pharma Limited","nameEN":"OKYO Pharma Limited","securityTypeName":"DR","adrRate":"1:65"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"OKYO Pharma Limited(OKYO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest OKYO Pharma Limited(OKYO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"OKYO Pharma Limited,OKYO,OKYO Pharma Limited股票,OKYO Pharma Limited股票老虎,OKYO Pharma Limited股票老虎国际,OKYO Pharma Limited行情,OKYO Pharma Limited股票行情,OKYO Pharma Limited股价,OKYO Pharma Limited股市,OKYO Pharma Limited股票价格,OKYO Pharma Limited股票交易,OKYO Pharma Limited股票购买,OKYO Pharma Limited股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"OKYO Pharma Limited(OKYO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest OKYO Pharma Limited(OKYO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction